• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾移植与肝移植受者移植后淋巴细胞增生性疾病风险及预后因素的比较

Comparison of Post-Transplantation Lymphoproliferative Disorder Risk and Prognostic Factors between Kidney and Liver Transplant Recipients.

作者信息

Mucha Krzysztof, Staros Rafał, Foroncewicz Bartosz, Ziarkiewicz-Wróblewska Bogna, Kosieradzki Maciej, Nazarewski Sławomir, Naumnik Beata, Raszeja-Wyszomirska Joanna, Zieniewicz Krzysztof, Pączek Leszek

机构信息

Department of Immunology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-006 Warsaw, Poland.

Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warsaw, Poland.

出版信息

Cancers (Basel). 2022 Apr 13;14(8):1953. doi: 10.3390/cancers14081953.

DOI:10.3390/cancers14081953
PMID:35454860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9024969/
Abstract

Post-transplantation lymphoproliferative disorder (PTLD) is a life-threatening complication of solid organ transplantation (SOT). Its development risk varies among organ graft recipients. In this study, retrospective data were analyzed to compare PTLD’s risk and prognostic factors between adult kidney and liver transplant recipients (KTRs and LTRs, respectively). Over 15 years, 2598 KTRs and 1378 LTRs were under observation at our center. Sixteen KTRs (0.62%) and twenty-three LTRs (1.67%) were diagnosed with PTLD. PTLD developed earlier in LTRs (p < 0.001), SOT patients > 45 years old (p = 0.002), and patients receiving tacrolimus (p < 0.001) or not receiving cyclosporin (p = 0.03) at diagnosis. Tacrolimus use, male sex, and age > 45 years old significantly affected the time of PTLD onset in KTRs (hazard ratio (HR) = 18.6, 7.9 and 5.2, respectively). Survival was longer in LTRs < 45 years old (p < 0.009). LTRs were more likely than KTRs to achieve complete remission (p = 0.039). Factors affecting PTLD development and outcome differ between KTRs and LTRs; thus, these populations should be separately evaluated in future studies.

摘要

移植后淋巴细胞增生性疾病(PTLD)是实体器官移植(SOT)的一种危及生命的并发症。其发生风险在器官移植受者中各不相同。在本研究中,分析回顾性数据以比较成年肾移植受者和肝移植受者(分别为KTRs和LTRs)中PTLD的风险及预后因素。在15年多的时间里,本中心观察了2598例KTRs和1378例LTRs。16例KTRs(0.62%)和23例LTRs(1.67%)被诊断为PTLD。PTLD在LTRs中出现得更早(p<0.001),在年龄>45岁的SOT患者中出现得更早(p = 0.002),且在诊断时使用他克莫司的患者中出现得更早(p<0.001)或未接受环孢素的患者中出现得更早(p = 0.03)。使用他克莫司、男性性别以及年龄>45岁显著影响KTRs中PTLD的发病时间(风险比(HR)分别为18.6、7.9和5.2)。年龄<45岁的LTRs生存率更长(p<0.009)。LTRs比KTRs更有可能实现完全缓解(p = 0.039)。影响PTLD发生和结局的因素在KTRs和LTRs之间有所不同;因此,在未来的研究中应对这些人群进行分别评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/2b41ac1a61b2/cancers-14-01953-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/bacb4b458c6d/cancers-14-01953-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/80e12dce87bf/cancers-14-01953-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/2b41ac1a61b2/cancers-14-01953-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/bacb4b458c6d/cancers-14-01953-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/80e12dce87bf/cancers-14-01953-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d3d/9024969/2b41ac1a61b2/cancers-14-01953-g003.jpg

相似文献

1
Comparison of Post-Transplantation Lymphoproliferative Disorder Risk and Prognostic Factors between Kidney and Liver Transplant Recipients.肾移植与肝移植受者移植后淋巴细胞增生性疾病风险及预后因素的比较
Cancers (Basel). 2022 Apr 13;14(8):1953. doi: 10.3390/cancers14081953.
2
Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.特发性肺纤维化肺移植受者发生 EBV 相关移植后淋巴组织增生性疾病的风险增加,且生存情况更差。
Am J Transplant. 2020 May;20(5):1439-1446. doi: 10.1111/ajt.15756. Epub 2020 Jan 22.
3
Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.心脏和肾脏移植患者的移植后淋巴细胞增生性疾病:单中心经验
J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83. doi: 10.1177/107424840601100107.
4
Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplant recipients.肺移植受者移植后淋巴组织增生性疾病的系统评价和荟萃分析。
Clin Transplant. 2018 May;32(5):e13235. doi: 10.1111/ctr.13235. Epub 2018 Mar 30.
5
Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry.肺移植患者移植后淋巴组织增生性疾病的发生率和结果:ISHLT 登记处分析。
J Heart Lung Transplant. 2020 Oct;39(10):1089-1099. doi: 10.1016/j.healun.2020.06.010. Epub 2020 Jun 20.
6
Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection.非肾实体器官移植后的肾移植受者表现出低同种异体反应性,但感染风险增加。
Transpl Int. 2016 Dec;29(12):1296-1306. doi: 10.1111/tri.12856. Epub 2016 Sep 30.
7
Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.实体器官和造血干细胞移植后的移植后淋巴组织增生性疾病。
Leuk Lymphoma. 2019 Jan;60(1):142-150. doi: 10.1080/10428194.2018.1474462. Epub 2018 Jul 3.
8
Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.实体器官移植和血液系统干细胞移植后成人移植后淋巴细胞增殖性疾病有差异吗?41例患者的经验。
Br J Radiol. 2015 Aug;88(1052):20140861. doi: 10.1259/bjr.20140861. Epub 2015 May 20.
9
The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.30 多年来成人实体器官移植受者移植后淋巴增殖性疾病的变化:单中心经验。
Transplantation. 2018 Sep;102(9):1553-1562. doi: 10.1097/TP.0000000000002146.
10
Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.儿童心脏移植受者的移植后淋巴组织增生性疾病。
J Heart Lung Transplant. 2010 Jun;29(6):648-57. doi: 10.1016/j.healun.2010.01.013. Epub 2010 Mar 20.

引用本文的文献

1
Does the Organ Matter in PTLD Development in Solid Organ Transplant Recipients? A Multicenter Observational Study of Risk and Prognostic Factors.实体器官移植受者发生移植后淋巴增殖性疾病时器官是否起作用?一项关于风险和预后因素的多中心观察性研究。
Cancers (Basel). 2025 May 25;17(11):1770. doi: 10.3390/cancers17111770.
2
Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study.一项合作研究中移植后淋巴细胞增生性疾病的特征与转归
Front Oncol. 2023 Jun 23;13:1208028. doi: 10.3389/fonc.2023.1208028. eCollection 2023.
3
Perspectives for 3D-Bioprinting in Modeling of Tumor Immune Evasion.

本文引用的文献

1
Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders.移植后淋巴细胞增殖性疾病中的自然杀伤细胞
Cancers (Basel). 2021 Apr 12;13(8):1836. doi: 10.3390/cancers13081836.
2
Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein-Barr Virus (EBV) Assessments-A Single Tertiary Referral Center Experience and Review of Literature.通过爱泼斯坦-巴尔病毒(EBV)评估分析移植后淋巴细胞增生性疾病(PTLD)的预后——一家三级转诊中心的经验及文献综述
Cancers (Basel). 2021 Feb 21;13(4):899. doi: 10.3390/cancers13040899.
3
The Application of CAR-T Cells in Haematological Malignancies.
3D生物打印在肿瘤免疫逃逸建模中的应用前景
Cancers (Basel). 2022 Jun 26;14(13):3126. doi: 10.3390/cancers14133126.
嵌合抗原受体 T 细胞在血液系统恶性肿瘤中的应用。
Arch Immunol Ther Exp (Warsz). 2020 Nov 6;68(6):34. doi: 10.1007/s00005-020-00599-x.
4
Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.移植后淋巴细胞增生性疾病:当前概念与未来治疗方法
World J Transplant. 2020 Feb 28;10(2):29-46. doi: 10.5500/wjt.v10.i2.29.
5
Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder.影响移植后极晚期淋巴细胞增殖性疾病预后因素的单中心回顾性分析
Cureus. 2020 Feb 7;12(2):e6912. doi: 10.7759/cureus.6912.
6
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.现成的EBV特异性T细胞免疫疗法用于移植后利妥昔单抗难治性EBV相关淋巴瘤。
J Clin Invest. 2020 Feb 3;130(2):733-747. doi: 10.1172/JCI121127.
7
Very late onset post-transplant diffuse large B cell lymphoma in a liver transplant recipient with hepatitis B: A case report.一名乙型肝炎肝移植受者发生的极晚期移植后弥漫性大B细胞淋巴瘤:病例报告
Medicine (Baltimore). 2018 Nov;97(44):e13063. doi: 10.1097/MD.0000000000013063.
8
Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000.2000 年后肾移植患者中早发和晚发移植后淋巴组织增生性疾病的不同病因。
Asian J Surg. 2019 Apr;42(4):551-556. doi: 10.1016/j.asjsur.2018.09.002. Epub 2018 Oct 14.
9
Increased Incidence of Post-transplant Lymphoproliferative Disorder in Autoimmune Liver Disease: An Irish National Experience.自身免疫性肝病中移植后淋巴细胞增生性疾病的发病率增加:一项爱尔兰全国性经验。
J Clin Exp Hepatol. 2018 Mar;8(1):42-49. doi: 10.1016/j.jceh.2017.05.209. Epub 2017 Jun 15.
10
The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013.成人移植后淋巴组织增生性疾病的变化:1999 年至 2013 年间组织学的变化。
Am J Hematol. 2018 Jul;93(7):874-881. doi: 10.1002/ajh.25116. Epub 2018 May 6.